You are here: Industry Insights > Visterra

News List

Visterra Initiates Phase 1 Clinical Study of VIS649 americanpharmaceuticalreview
November 10, 2018
Visterra announced the initiation of a Phase 1 clinical study with VIS649 in healthy volunteers. VIS649 is a monoclonal
Otsuka Pharmaceutical Completes Acquisition of Visterra americanpharmaceuticalreview
September 05, 2018
Visterra announces that Otsuka Pharmaceutical has completed the acquisition of Visterra for approximately $430 million in an all-cash transaction. The acquisition was completed on August 31, 2018.
Japan's Otsuka Pharma to acquire Visterra for $430 mn biospectrumasia
July 19, 2018
Visterra's pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases.
Otsuka snaps up Visterra in $430 million deal pharmafile
July 17, 2018
Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an all-cash transaction to the value of $430 million.
Otsuka acquires Visterra for $430 M biospectrumasia
July 16, 2018
Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, and kidney, cardiovascular, and infectious diseases.
Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on R biospace
March 08, 2018
Visterra Corporation today announced the release of VIS410 new preclinical data at the 2nd International Conference of Respiratory Pathogens at the Copthorne Hotel Singapore